Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Ezra E.W. Cohen"'
Autor:
Alaa Kandil, Qingyuan Zhang, Yuan Geng, C.-H. Wang, Ping Zhang Tang, S.-B. Kim, Ezra E.W. Cohen, Ye Guo, Vijay Kumar, R.S. Arora, Xiaohui He, Arunee Dechaphunkul, Myung-Ju Ahn, Jin Hyoung Kang, Wei Li, P. Li, Krishna M. Kamble, M. Bello, Andrew T. Chan, E. Zografos
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology, vol 30, iss 11
Annals of Oncology
Annals of Oncology
Author(s): Guo, Y; Ahn, M-J; Chan, A; Wang, C-H; Kang, J-H; Kim, S-B; Bello, M; Arora, RS; Zhang, Q; He, X; Li, P; Dechaphunkul, A; Kumar, V; Kamble, K; Li, W; Kandil, A; Cohen, EEW; Geng, Y; Zografos, E; Tang, PZ | Abstract: BackgroundTreatment opti
Autor:
Kathryn A. Gold, Ezra E.W. Cohen, Christopher D. Fischer, Christopher Joseph Sumey, Ryan Kenneth Nowak, Steven McGraw, Paul A. Thompson, William C. Spanos, Juan Luis Callejas-Valera, Ashley Wayne Jensen, Miran J. Blanchard, Michele Lohr, Lora Jane Black, Mark M. Gitau, Julie Bykowski, Steven Francis Powell, Christie Ellison, John H. Lee
Publikováno v:
J Clin Oncol
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 38, iss 21
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 38, iss 21
PURPOSE Pembrolizumab is a humanized monoclonal antibody that blocks interaction between programmed death receptor-1 (PD-1) and its ligands (PD-L1, PD-L2). Although pembrolizumab is approved for recurrent/metastatic head and neck squamous cell carcin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19be478bffc9e3635bed30f4041686a2
https://europepmc.org/articles/PMC7365766/
https://europepmc.org/articles/PMC7365766/
Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4
Autor:
Panomwat Amornphimoltham, Victoria Wu, J. Silvio Gutkind, James D. McDermott, J. Guy Lyons, Juan Luis Callejas-Valera, Bryan S. Yung, Michael M. Allevato, Ezra E.W. Cohen, Yusuke Goto, Lynn Vitale-Cross, Zhiyong Wang, Mara Gilardi, Yudou He, Andrew B. Sharabi, Daniel Martin, Qianming Chen, Ludmil B. Alexandrov, Alfredo A. Molinolo
Publikováno v:
Nature communications, vol 10, iss 1
Nature Communications, Vol 10, Iss 1, Pp 1-13 (2019)
Nature Communications
Nature Communications, Vol 10, Iss 1, Pp 1-13 (2019)
Nature Communications
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide. Tobacco use is the main risk factor for HNSCC, and tobacco-associated HNSCCs have poor prognosis and response to available treatments. Recently approved anti-PD-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::299dcf1ff705509eac8f0874ced87c05
https://escholarship.org/uc/item/88z6v6vs
https://escholarship.org/uc/item/88z6v6vs
Autor:
Ezra E.W. Cohen, Frank Worden, David N. Hayes, Heinz-Josef Lenz, Albiruni Ryan Abdul Razak, John D. Roberts, Nabil F. Saba, Kevin J. Cullen, D. Lim, Naoko Takebe, Merrill S. Kies, Jill Gilbert, Athanassios Argiris, Tawee Tanvetyanon, Theodore Karrison, Stuart J. Wong, Everett E. Vokes
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology, vol 27, iss 2
Background Adenoid cystic carcinoma (ACC) is a subtype of malignant salivary gland tumors (MSGT), in which 90% of cases express cKIT. Dasatinib is a potent and selective inhibitor of five oncogenic protein tyrosine kinases (PTKs)/kinase families incl
Autor:
Maria Luisa Carcangiu, Madhavi Nagilla, Laura D. Locati, Poluru L. Reddy, Tanguy Y. Seiwert, Ezra E.W. Cohen, Giuseppe Pelosi, Rebecca B. Schechter, Sydeaka Watson, Arun Khattri, Loren Joseph, Lisa Licitra, Angela Greco, Mark W. Lingen
Publikováno v:
Cancer Letters. 359:269-274
Biomarkers predicting which patients with advanced radioiodine-resistant differentiated thyroid cancer (DTC) may benefit from multi-kinase inhibitors are unavailable. We aimed to describe molecular markers in DTC that correlate with clinical outcome
Autor:
Se-Hoon Lee, Yung-Jue Bang, Qing Sheng, Thiruvamoor Ramkumar, Xianbin Tian, Maria Alsina, Abdelkader Seroutou, Rose Fernandez, Sunil Sharma, Kerry L. Reynolds, Philippe L. Bedard, Josep Tabernero, Donna M. Graham, Alex Morozov, Chia-Chi Lin, Dejan Juric, Angela Zubel, Ignacio Garrido-Laguna, José Baselga, George R. Blumenschein, Ezra E.W. Cohen, Ravi Salgia
Publikováno v:
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
BMC Cancer
BMC cancer, vol 17, iss 1
BMC Cancer, Vol 17, Iss 1, Pp 1-11 (2017)
Universitat Autònoma de Barcelona
BMC Cancer
BMC cancer, vol 17, iss 1
BMC Cancer, Vol 17, Iss 1, Pp 1-11 (2017)
Altres ajuts: This study was funded by Novartis Pharmaceuticals Corporation (study design,collection, analysis, and interpretation of data, and medical editorial writing assistance). Human epidermal growth factor receptor 3 (HER3) is important in mai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e9ba3f00e62b574ab3ea254c926c7a9
https://ddd.uab.cat/record/186327
https://ddd.uab.cat/record/186327
Autor:
Richard A. Graham, Mark J. Ratain, Naoko Takebe, Michael L. Maitland, Richard L. Schilsky, Theodore Karrison, David Geary, Ezra E.W. Cohen, Kehua Wu, Soonmo Peter Kang, Bethany Kell, Michelle Turcich, Manish R. Sharma
Publikováno v:
Clinical Cancer Research. 19:3059-3067
Purpose: Vismodegib, an orally bioavailable small-molecule Smoothened inhibitor, is approved for treatment of advanced basal cell carcinoma (BCC). We conducted a pharmacokinetic study of vismodegib in patients with advanced solid tumors to explore th
Autor:
Everett E. Vokes, Tanguy Y. Seiwert, Cesar A. Perez, Hunho Song, Ezra E.W. Cohen, Olufunmilayo I. Olopade, Mark Agulnik, Luis E. Raez, Elizabeth A. Blair, Kerstin M. Stenson, Tatyana A. Grushko, Allison Dekker
Publikováno v:
Oral Oncology. 48:887-892
Gefitinib has activity in patients with advanced squamous cell carcinoma of the head and neck (SCCHN) and skin toxicity has been postulated to be a predictor of response and improved outcome.This open-label, multi-institution, phase II study evaluate
Autor:
Ezra E.W. Cohen, Lori J. Wirth, Marcia S. Brose, Steven I. Sherman, Huibin Yue, Maria E. Cabanillas, Eric J. Sherman, Todd Riehl
Publikováno v:
The Lancet. Oncology, vol 17, iss 9
Summary Background About half of patients with papillary thyroid cancer have tumours with activating BRAF V600E mutations. Vemurafenib, an oncogenic BRAF kinase inhibitor approved for BRAF -positive melanoma, showed clinical benefit in three patients
Autor:
Mark J. Ratain, Arlene A. Forastiere, Lei Ye, Robert F. Gagel, Ezra E.W. Cohen, Linda Janisch, Steven I. Sherman, Forlisa Nauling, David S. Hong, Chaan S. Ng, Razelle Kurzrock, Thomas Müller, Ranee Mehra, Douglas W. Ball, John W. Frye, David G. Pfister, Roger B. Cohen, Ravi Salgia
Publikováno v:
Journal of Clinical Oncology. 29:2660-2666
Purpose XL184 (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models. Early observations of clinical benefit